Tempest Therapeutics (TPST) - Long-Term Debt to Capital

Tempest Therapeutics (TPST) relies on outsourcing for production and testing, maintaining the flexibility of its scientific team. This long-term debt-to-equity ratio chart demonstrates financial leverage, with the metric holding at 0.00. The business is independent of economic cycles, and the development of targeted liver cancer therapies provides the company with an active growth phase.

This ratio determines the extent of the company's dependence on debt capital with a long-term repayment horizon. The algorithm compares the volume of long-term loans against the amount of equity to assess financial stability. By analyzing the ratio of long-term liabilities to equity, an investor identifies risks of excessive debt load. For Tempest Therapeutics (TPST), this balance is critical for covering fixed laboratory costs. Low leverage confirms the viability of a strategy that delegates commercialization to partners in exchange for royalties.